ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2171

Identification Of Best Cutoff Points and Clinical Signs Specific For Early Recognition Of Macrophage Activation Syndrome In Active Systemic Juvenile Idiopathic Arthritis

Mikhail Kostik1, Margarita Dubko2, Ludmila Snegireva1, Vera Masalova1, Tatyana Kornishina2, Natalya Abramova3, Irina Chikova2, Natalya Glebova3, Ekaterina Kuchinskaya3, Eugenia Balbotkina3, Olga Kalshnikova3 and Vyacheslav Chasnyk4, 1Hospital Pediatrics, State Pediatric Medical University, Saint-Petersburg, Russia, 2State Pediatric Medical University, Saint-Petersburg, Russia, 3Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, 4Hospital Pediatry, State Pediatric Medical University, Saint-Petersburg, Russia

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Systemic JIA and macrophage activation syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology-Clinical and Therapeutic Aspects III: Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Macrophage activation syndrome (MAS) – is a severe life-threatening hematological condition, mostly complicated systemic juvenile idiopathic arthritis (SJIA). Early detection of MAS can lead to appropriate therapeutic interventions and change the outcomes. There are no strict criteria for early MAS detection in SJIA. Currently applied HLH criteria can determinate only advanced stage of MAS, which lead to delay diagnosis, late start of specific treatment and associated with poor outcomes. There are several sets of preliminary criteria of MAS in SJIA.

The aim of our study was to detect early clinical and laboratorial signs able to discriminate MAS from active SJIA without MAS. 

Methods:

our retrospective study was based on reviewing of medical charts of children who were admitted to our rheumatology department in 2005-2013 with SJIA and definite MAS (n=18) and active SJIA without MAS (n=40). We utilized the A.Ravelli criteria (2002, 2005, 2011) for detecting MAS. We evaluated demographic data, data related to SJIA and MAS. We used the main characteristic clinical and laboratorial markers of MAS only at the moment of MAS confirmation. We calculated cutoff points for MAS parameters (ROC-analysis), performed analysis of sensitivity and specificity and identified predictors.

Results:

Several clinical signs were relevant to MAS in SJIA: oligoarthicular disease course (OR=5.6 [95%CI:1.6-19.4], p=0.005), splenomegaly (OR=67.6 [3.8-1205.9], p=0.000004), coagulopathy (OR=7.0 [1.9-26.1], p=0.006), lung (OR=11.3 [2.8-45.2], p=0.0001) and kidney involvement, realized in proteinuria<1.0g/24 h (OR=42.1 [2.2-801.2], p=0.0001). The involvement of wrist (OR=0.2 [0.1-0.8], p=0.03), MCP (OR=0.1 [0.0-0.9], p=0.02) and PIP joints (OR=0.1 [0.0-0.6], p=0.005) were protective against MAS development. The best cutoffs for laboratorial parameters, related to MAS are in table.

Parameter

Sensitivity

Specifisity

OR (95%CI)

AUC (95%CI)

p

Hb≤90 g/l

72.2

80.0

10.4 (2.9-37.8)

0.77 (0.64-0.87)

0.0001

WBC≤9.9*109/l

83.3

90.0

35.0 (7.4-165.6)

0.92 (0.81-0.97)

0.0000001

PLT≤211*109/l

88.9

100.0

534.6 (24.3-1747.8)

0.98 (0.9-0.997)

0.0000001

ALT>72.9 U/l

64.7

85.0

10.4 (2.8-38.9)

0.81 (0.68-0.9)

0.0002

AST>59.7 U/l

82.4

92.1

54.4 (9.8-302.9)

0.88 (0.76-0.95)

0.0000001

LDH>882 U/l

75.0

100.0

158.3 (7.9-3169.1)

0.91 (0.79-0.976)

0.0000001

GGTP>35 U/l

83.3

60.0

7.5 (1.2-47.1)

0.68 (0.47-0.85)

0.047

ALP>736.2

27.3

100.0

30.1 (1.4-638.4)

0.58 (0.43-0.72)

0.01

Total protein≤63g/l

64.7

97.5

71.5 (7.8-658.5)

0.84 (0.71-0.92)

0.0000001

Albumin≤29.3 g/l

100.0

92.5

375.0 (18.4-7661.8)

0.98 (0.9-0.997)

0.0000001

Prothrombin≤77%

71.4

92.3

30.0 (2.9-313.5)

0.81 (0.61-0.93)

0.0008

Fibrinogen≤1.8 g/l

64.3

100.0

46.6 (2.3-947.8)

0.88 (0.7-0.97)

0.001

Ferritin>400 μg/l

100.0

76.0

87.0 (4.5-1671.7)

0.92 (0.78-0.98)

0.000005

CRP>113 mg/l

52.9

89.5

9.6 (2.3-39.1)

0.59 (0.45-0.72)

0.001

ESR≤10 mm/h

61.1

92.5

19.4 (4.3-87.8)

0.78 (0.65-0.88)

0.0001

Na+ ≤137 mmol/l

66.7

81.1

8.0 (2.1-31.0)

0.79 (0.65-0.0.89)

0.003

Active joints≤6

83.3

59.0

7.2 (1.8-29.0)

0.74 (0.61-0.85)

0.003

Conclusion:

we detected clinical and laboratorial markers which can help to early recognition of

MAS in children with active SJIA.


Disclosure:

M. Kostik,
None;

M. Dubko,
None;

L. Snegireva,
None;

V. Masalova,
None;

T. Kornishina,
None;

N. Abramova,
None;

I. Chikova,
None;

N. Glebova,
None;

E. Kuchinskaya,
None;

E. Balbotkina,
None;

O. Kalshnikova,
None;

V. Chasnyk,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-best-cutoff-points-and-clinical-signs-specific-for-early-recognition-of-macrophage-activation-syndrome-in-active-systemic-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology